Companies / CHM

CHIMERIC THERAPEUTICS LIMITED

ASX:CHMPharmaceuticals, Biotechnology & Life SciencesSuspended from quotation
59.5M shares on issueASX (delayed) · as of 28 July 2026$0.036price · delayed$2.1Mmarket cap · indicative
NR
Dilution grade

Not rated — the company is suspended from quotation

Cash runwayno data — suspended — grade not computed
Share-count growth (24m)no data — suspended — grade not computed
Raise cadence (24m)0 cash raises
Options & rights overhangno dataconsolidation-adjusted
In-the-money supplyno data — no recent share price on record
Pending proposed issuesnone

CHIMERIC THERAPEUTICS LIMITED's latest ordinary share count stands at 59M as of July 2026; this figure is adjusted for an approximately 1-for-98.4 share consolidation that occurred in April 2026. The company raised capital ten times over the past 24 months for total confirmed proceeds of A$18.0M, most recently a A$4.4M placement in December 2025. No proposed securities issues (Appendix 3B) are pending. At the March 2026 quarter the reported cash position was A$-2.8M.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
11.8%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
-0.8 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Adjusted for the 1-for-98.4 consolidation (28 Apr 2026). Latest count 59.5M per ASX (delayed) (28 July 2026).
53.4M55.6M57.9MMay 26June 26July 26

Cash runway

-0.8 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$-2.8M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
22 July 20262A · quoted issueCHM : ORDINARY FULLY PAID59.5MAppendix 2A
17 July 20263G · unquotedORDINARY FULLY PAID57.9MAppendix 3G
17 July 20263G · unquotedCHM : ORDINARY FULLY PAID57.9MAppendix 3G
14 July 20262A · quoted issueCHM : ORDINARY FULLY PAID57.9MAppendix 2A
14 July 20263H · cancellationCHM : ORDINARY FULLY PAID56.5MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

10 cash raises in the last 24 months · 2 in the last 12 months

$4.4M
Placement
23 Dec 2025 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

consolidation-adjusted Figures rebased for the share consolidation in the last 24 months.

11.8%
Total overhang · of current shares
0.0%
In the money · at current price
7.0M
Potential new shares
Oct 2028
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
19 Dec 2025Miles PrinceOther—16.7M—3Y notice
19 Aug 2025Miles PrinceBuy4.3M——3Y notice
26 June 2025Lesley RussellSell—2.8M—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

28 July 2026Investor Presentation
22 July 2026Application for quotation of securities - CHM
17 July 2026Notification regarding unquoted securities - CHM
17 July 2026Notification regarding unquoted securities - CHM
15 July 2026$PCHM CDH17 Phase 1 clinical trial update - New DL 3 data
14 July 2026Application for quotation of securities - CHM
14 July 2026Notification of cessation of securities - CHM
7 July 2026Final Director's Interest Notice
5 July 2026Board Update
2 July 2026Application for quotation of securities - CHM
30 June 2026$PAppointment of Financial Adviser for Strategic Review
11 June 2026Application for quotation of securities - CHM
1 June 2026Application for quotation of securities - CHM
31 May 2026$PCHM announces positive Phase 1/2 data at ASCO
20 May 2026Application for quotation of securities - CHM
12 May 2026Notice under section 708A
12 May 2026Application for quotation of securities - CHM
12 May 2026Application for quotation of securities - CHM
8 May 2026Proposed issue of securities - CHM
5 May 2026Notification of cessation of securities - CHM

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.